U.S. markets closed
  • S&P Futures

    3,652.25
    -2.00 (-0.05%)
     
  • Dow Futures

    29,246.00
    -39.00 (-0.13%)
     
  • Nasdaq Futures

    11,211.75
    -16.50 (-0.15%)
     
  • Russell 2000 Futures

    1,680.80
    -1.30 (-0.08%)
     
  • Crude Oil

    81.23
    0.00 (0.00%)
     
  • Gold

    1,672.00
    +3.40 (+0.20%)
     
  • Silver

    18.84
    +0.13 (+0.68%)
     
  • EUR/USD

    0.9829
    +0.0010 (+0.10%)
     
  • 10-Yr Bond

    3.7470
    +0.0420 (+1.13%)
     
  • Vix

    31.84
    +1.66 (+5.50%)
     
  • GBP/USD

    1.1162
    +0.0039 (+0.35%)
     
  • USD/JPY

    144.7000
    +0.2570 (+0.18%)
     
  • BTC-USD

    19,538.99
    +97.40 (+0.50%)
     
  • CMC Crypto 200

    446.23
    +0.25 (+0.06%)
     
  • FTSE 100

    6,881.59
    -123.80 (-1.77%)
     
  • Nikkei 225

    26,077.20
    -344.85 (-1.31%)
     

Aptinyx Announces Formation of Scientific Advisory Board

·3 min read

Leading experts in neuroscience will provide guidance to support the advancement of Aptinyx’s novel NMDA receptor modulation platform and pipeline

EVANSTON, Ill., February 03, 2022--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the formation of its Scientific Advisory Board (SAB), comprising leading researchers and physicians in the areas of neuropsychiatry, neurology, and chronic pain. The SAB will work closely with the Aptinyx management team to provide scientific and clinical input into the investigation, characterization, and therapeutic application of the novel NMDA receptor modulation mechanism underpinning the company’s platform and development pipeline.

The inaugural cohort of SAB members include:

  • Chadi Abdallah, M.D. – Associate Professor and the Beth K. and Stuart C. Yudofsky Chair in the Neuropsychiatry of Military Post-Traumatic Stress Syndrome at the Baylor College of Medicine

  • Lesley Arnold, M.D. – Professor of Psychiatry & Behavioral Neuroscience and Director of the Women’s Health Research Program at the University of Cincinnati College of Medicine

  • Peter LeWitt, M.D. – Professor of Neurology and Sastry Foundation Endowed Chair in Neurology at the Wayne State University School of Medicine and Former Director of the Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital

  • Gerard Sanacora, M.D., Ph.D. – George D. and Esther S. Gross Professor of Psychiatry at the Yale University School of Medicine, Director of the Yale Depression Research Program, and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service

"We are honored to be working with this group of distinguished healthcare leaders and appreciate their support of our research and development efforts," said Andy Kidd, M.D., president and chief executive officer of Aptinyx. "The engagement of these world-class neuroscience experts underscores the therapeutic potential of Aptinyx’s novel NMDA receptor modulation technology platform. Moving forward, our Scientific Advisory Board will play an important role in helping to inform and guide our research and development activities as we seek to bring new therapies to people grappling with serious neurologic and psychiatric disorders."

About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company’s business plans and objectives, the company’s belief in the therapeutic potential of our product candidates, and the expected impact and contribution of our scientific advisors to our business. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the company’s product candidate development activities and planned clinical studies; the company’s ability to execute on its strategy; as well as those risks and uncertainties set forth in the company’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005323/en/

Contacts

Investor & Media Contact:
Patrick Flavin
Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com
847-871-0377